RESUMO
Lawrence transfer factor (TF) is defined as dialyzable leukocyte extract (DLE) that can transfer antigen-specific cell-mediated immunity from a person testing positive for the antigen in a delayed type hypersensitivity skin test manner to a person negative for the same antigen. A recent article by Myles et al1 has identified a DLE isolated from an established CD8+ T cell line capable of transferring antigen-specific immunity. The DLE contains a portion of the beta chain of the T cell receptor and additional nucleotide and protein factors that are being subjected to further modern biochemical analysis. After months of study that included interviews of TF physician-scientists, we conclude that an antigen-specific TF exists for most, if not all, antigens. By working from a CD8+ T cell line with modern biochemical technology, it should be possible to identify and patent products capable of treating infectious diseases, antigen-responsive cancers, and autoimmune disorders.
Assuntos
Linfócitos T CD8-Positivos/imunologia , Fator de Transferência/imunologia , Linhagem Celular , Humanos , Imunidade Celular , Memória ImunológicaRESUMO
Leprosy is a disease caused by Mycobacterium leprae that presents on a spectrum of both clinical manifestations and T cell response. On one end of this spectrum, tuberculoid leprosy is a well-controlled disease, characterized by a cell-mediated immunity and immunosurveillance. On the opposite end of the spectrum, lepromatous leprosy is characterized by M. leprae proliferation and T cell anergy. Similar to progressive tumor cells, M. leprae escapes immunosurveillance in more severe forms of leprosy. The mechanisms by which M. leprae is able to evade the host immune response involve many, including the alterations of lipid droplets, microRNA, and Schwann cells, and involve the regulation of immune regulators, such as the negative checkpoint regulators CTLA-4, programmed death 1, and V-domain Ig suppressor of T cell activation-important targets in today's cancer immunotherapies. The means by which tumor cells become able to escape immunosurveillance through negative checkpoint regulators are evidenced by the successes of treatments, such as nivolumab and ipilimumab. Many parallels can be drawn between the immune responses seen in leprosy and cancer. Therefore, the understanding of how M. leprae encourages immune escape during proliferative disease states has potential to add to our understanding of cancer immunotherapy.
Assuntos
Imunidade Celular/imunologia , Hanseníase/imunologia , Modelos Biológicos , Neoplasias/imunologia , Linfócitos T/imunologia , Animais , Humanos , Ativação LinfocitáriaRESUMO
Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of melanoma. Although to date the compound is not approved as a drug by the FDA or EMA, physicians have continued to use DPCP because of its proven effects in these dermatological conditions. The use of the drug has been highly variable because of differences in compounding, and as a result, the literature reports vary widely in the concentrations used for sensitization and challenge treatment with DPCP. The efficacy of DPCP has generally been ascribed to immunological reactions by the host. Inducing inflammation with a contact sensitizer is counterintuitive to treating AA, an autoimmune disorder. We have hypothesized that the body's attempt to downregulate the inflammation caused by the contact sensitizer may also ameliorate AA. Studies using microarray and miRNA profiling may provide information about how DPCP induces inflammation in human skin at different times. Gene targets and microRNAs identified through these data may be modulated by an RNA interference approach to enhance DPCP efficacy and response rates. In addition, this approach may result in the discovery and development of drugs that are more potent and selective for the treatment of AA.
Assuntos
Alopecia em Áreas/tratamento farmacológico , Ciclopropanos/farmacologia , Fármacos Dermatológicos/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Inflamação/genética , Interferência de RNA , Alopecia em Áreas/genética , Alopecia em Áreas/imunologia , Doenças Autoimunes/tratamento farmacológico , Terapia Combinada , Ciclopropanos/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Regulação para Baixo , Humanos , Inflamação/tratamento farmacológico , Regulação para CimaAssuntos
Fibrilação Atrial/fisiopatologia , MicroRNAs/fisiologia , Linfócitos T/fisiologia , Fibrilação Atrial/complicações , Fibrilação Atrial/imunologia , Doença Celíaca/complicações , Doença Celíaca/epidemiologia , Doença Celíaca/imunologia , Humanos , Psoríase/complicações , Psoríase/epidemiologia , Psoríase/imunologiaRESUMO
MicroRNAs (miRNAs) are small, noncoding regulatory RNAs demonstrated to play a role in regulating diverse physiologic and pathologic processes in humans. The understanding of their role in dermatologic disorders has been rapidly expanding, and technological advances in the field of small RNA therapeutics have provided a window into the possibilities for using our understanding of miRNA activities as a stepping-stone to treating a variety of skin diseases. The topical immunomodulator diphenylcyclopropenone (DPCP) has been used for the treatment of skin cancers and alopecia areata and represents one of many drug targets with potential for manipulation of miRNA pathways to enhance clinical efficacy. By exploring the miRNA pathways involved in specific skin diseases and the miRNAs impacted by drug treatments, investigators will discover new ways to treat skin disease and improve preexisting therapies.
Assuntos
MicroRNAs/fisiologia , Dermatopatias/tratamento farmacológico , Administração Tópica , Ciclopropanos/administração & dosagem , Ciclopropanos/uso terapêutico , Humanos , MicroRNAs/efeitos dos fármacos , MicroRNAs/genéticaRESUMO
Ingenol mebutate is a diterpene ester derived from the plant Euphorbia peplus and is FDA approved for the topical treatment of actinic keratoses (AK). Shown to be efficacious with as little as a 3-day trial, this compound is being further tested for the topical treatment of other nonmelanoma skin cancers with promising preclinical data. In an effort to elucidate the molecular mechanism of this novel drug, Stahlhut et al. (2012) suggest a role for calcium and apoptosis. Further studies are needed to evaluate the intracellular mechanisms of ingenol mebutate-mediated cytotoxicity. Additionally, studies such as this not only shed light on the mechanism of ingenol mebutate and its derivatives, but also pave the way for evaluating the involvement of the immune system in eliminating drug-treated cells and tissues. This has important implications for the development of novel topical immune modulatory products and the field of topical immunotherapy.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Diterpenos/uso terapêutico , Fatores Imunológicos/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Animais , Apoptose/efeitos dos fármacos , Humanos , Ceratose Actínica/tratamento farmacológico , Transdução de Sinais/efeitos dos fármacosRESUMO
When simple chemical are applied to the skin, a series of events ensues that under some conditions ultimately results in contact sensitivity (CS), a proven cell-mediated immune response (CMI). Since the discovery of CMI using picryl-Cl (PCl) in 1942, we have learned a great deal on the cellular mechanisms involved in CS, including the potential to treat warts, skin cancer, autoimmune disorders, and allergies. In this review we summarize some of the basic mechanisms of both the innate and acquired immune systems involved in CS.
Assuntos
Dermatite Alérgica de Contato/imunologia , Dermatite Alérgica de Contato/metabolismo , Linfócitos T/imunologia , Animais , Linfócitos B/imunologia , Humanos , Queratinócitos/imunologia , Células Matadoras Naturais/imunologia , Células de Langerhans/imunologia , Mastócitos/imunologia , MicroRNAs/metabolismo , Receptores Toll-Like/metabolismoRESUMO
BACKGROUND: The longstanding concept of a Th1-Th2 dichotomy in leprosy, with Th1-predominant tuberculoid leprosy and Th2-predominant lepromatous leprosy (LL), has recently been challenged, and Cbl-b overexpression may emerge as an important factor in anergy and progression of LL. Moreover, Th17 and Th22 subsets have been identified as Th1-Th2 modulators in inflammatory skin diseases, most notably psoriasis, but their roles in leprosy have not yet been elucidated. The occurrence of pseudoepitheliomatous hyperplasia (PEH) with transepidermal elimination of mycobacteria in LL patients, which could theoretically be a portal for contact transmission, thus raises important immunological questions: Do Th17 and/or Th22 subsets mediate epidermal proliferation akin to Th1-driven psoriasis in supposedly Th2-predominant LL disease, and is the Th1-Th2 immunostat set systemically or locally? Furthermore, which microRNAs (miRs), signal transducers, and activators of transcription (STAT) proteins regulate this transition in leprosy, if any, and does differential Cb1-b expression play a role? OBSERVATION: A 71-year-old man presented with an infiltrative dermopathy characteristic of LL, as well as several hyperkeratotic plaques. Microscopic examination of the hyperkeratotic lesions demonstrated PEH with loss of the grenz zone and transepidermal elimination of acid-fast bacilli, whereas classic histopathologic features of LL were present at other sites. HYPOTHESES: We hypothesize that: Th17 and Th22 T-cell subsets act locally to induce T-cell plasticity in LL lesions, manifesting PEH; miR-181a is normal or increased in LL lesions with PEH compared to its expressional loss in classic LL lesions; miR-21 and STAT3 are increased in LL lesions with PEH, given their association with epithelial hyperproliferation; and Cbl-b is diminished in LL lesions with PEH compared to classic LL lesions. CONCLUSION: By understanding the factors that regulate T-cell and cytokine responses in leprosy, it should be possible to recognize these dynamic immunologic processes clinically and histopathologically and devise specific immunologic interventions.
Assuntos
Hanseníase Virchowiana/imunologia , Hanseníase Virchowiana/patologia , Pele/patologia , Idoso , Humanos , Hiperplasia/complicações , Hiperplasia/imunologia , Hiperplasia/patologia , Hanseníase Virchowiana/complicações , Masculino , Linfócitos T Auxiliares-Indutores/imunologiaRESUMO
Minocycline has been used in the treatment of leprosy since the demonstration of its efficacy in inhibiting Mycobacterium leprae growth in 1987. Hyperpigmentation, a well-documented adverse effect, classically shows 3 clinical and histological patterns: type I consists of blue-black pigmentation in areas of current or previous inflammation, type II consists of blue-gray pigmentation of normal skin, often seen on the legs, and type III consists of diffuse muddy-brown pigmentation accentuated on sun-exposed sites. Whereas type I hyperpigmentation stains positively for hemosiderin and type III hyperpigmentation stains positively for melanin, type II hyperpigmentation stains positively for both. We describe 2 patients with leprosy on minocycline therapy who developed multiple patches of blue-gray pigmentation within preexisting leprosy lesions. Biopsies from both patients demonstrated deposition of brownish-black pigment granules within the cytoplasm of foamy histiocytes that was highlighted by both Perls and Fontana-Masson stains. Given the clinical and histological findings in our patients, it is as yet unclear whether this coexistent type I clinical pattern and type II histopathologic pattern of pigmentation is unique to multibacillary leprosy. These findings provide support for the existence of additional subtypes of minocycline-induced hyperpigmentation that do not adhere to the classic 3-type model described.
Assuntos
Antibacterianos/efeitos adversos , Hiperpigmentação/induzido quimicamente , Hiperpigmentação/patologia , Hanseníase Multibacilar/tratamento farmacológico , Minociclina/efeitos adversos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Leprosy was the first disease classified according to the thymus derived T-cell in the 1960s and the first disease classified by the cytokine profile as intact interferon-γ (IFN-γ) and interleukin-2 (IL2) or TH1 (tuberculoid) and deficient IFN-γ and IL2 or TH2 (lepromatous), in the 1980s. OBJECTIVE: In the present study, we set out to explore the T helper 17 (TH17) lymphocyte subset, the hallmark of T-cell plasticity, in skin biopsies from patients with erythema nodosum leprosum (ENL) who were treated with thalidomide. METHOD: RNA was extracted from paraffin embedded tissue before and after thalidomide treatment of ENL and RT-PCR was performed. RESULTS: IL17A, the hallmark of TH17, was consistently seen before and after thalidomide treatment, confirming the TH17 subset to be involved in ENL and potentially up-regulated by thalidomide. CONCLUSION: A reduction in CD70, GARP, IDO, IL17B (IL-20), and IL17E (IL-25), coupled with increases in RORγT, ARNT, FoxP3, and IL17C (IL-21) following thalidomide treatment, opens the door to understanding the complexity of the immunomodulatory drug thalidomide, which can operate as an anti-inflammatory while simultaneously stimulating cell-mediated immunity (CMI). We conclude that TH17 is involved in the immunopathogenesis of ENL and that thalidomide suppresses inflammatory components of TH17, while enhancing other components of TH17 that are potentially involved in CMI.
Assuntos
Eritema Nodoso/imunologia , Hanseníase Virchowiana/imunologia , Células Th17/imunologia , Talidomida/uso terapêutico , Adolescente , Adulto , Biópsia , Citocinas/imunologia , Eritema Nodoso/tratamento farmacológico , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Interleucina-17/genética , Interleucina-17/imunologia , Hansenostáticos/farmacologia , Hansenostáticos/uso terapêutico , Hanseníase Virchowiana/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , RNA/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Talidomida/farmacologia , Regulação para Cima/efeitos dos fármacos , Adulto JovemAssuntos
Eritema Nodoso/complicações , Hanseníase Virchowiana/complicações , Hanseníase Multibacilar/complicações , Teste Tuberculínico/efeitos adversos , Adulto , Eritema Nodoso/tratamento farmacológico , Humanos , Testes de Liberação de Interferon-gama , Tuberculose Latente/diagnóstico , Hanseníase Virchowiana/tratamento farmacológico , Hanseníase Multibacilar/tratamento farmacológico , Masculino , Recidiva , Talidomida/uso terapêuticoRESUMO
CD70 (CD27L) has been shown to be preferentially expressed on Th1, but not Th2, CD4+ lymphocytes in murine contact sensitivity. The CD70-CD27 co-stimulatory pathway as well as the Th17 subset of lymphocytes have also been identified in human contact sensitivity reactions. The authors have previously reported increased expression of CD70 and the Th17-specific transcription factor retinoid orphan receptor gamma T in the elicitation phase of allergic contact dermatitis by reverse transcriptase-polymerase chain reaction. The manipulation of these pathways has potential for ameliorating autoimmune and inflammatory disorders such as allergic contact dermatitis, psoriasis and rheumatoid arthritis. Also, upregulation of the CD70-CD27 and Th17 pathways has been associated with the remarkable ability of topical sensitizers to treat warts and skin cancers including melanoma. As natural killer and natural killer T cells are also involved in contact sensitivity, future studies investigating the function of these cells are necessary to elucidate the transition between innate and acquired immune responses in the context of the Th1/Th2/Th17 and regulatory T cell paradigm.